Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

18.81 +0.44 (+2.40%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Don't Buy Summit Therapeutics Until This Big Thing Happen ↗

December 03, 2025

This biotech company is rolling the dice with a planned regulatory submission.

Via The Motley Fool

2 Monster Stocks in the Making to Buy and Hold ↗

December 02, 2025

There's still time to get in on these rising stars.

Via The Motley Fool

Summit SMMT Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Summit SMMT Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗

October 30, 2025

Via Benzinga

Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40% ↗

October 19, 2025

Via Stocktwits

An Overview of Summit Therapeutics's Earnings ↗

October 17, 2025

Via Benzinga

Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’ ↗

September 16, 2025

Via Stocktwits

Why Wall Street Is Backing These 3 Comeback Stocks ↗

October 28, 2025

Via MarketBeat

1 Monster Stock in the Making to Buy and Hold ↗

October 27, 2025

The company's prospects improve with every clinical win.

Via The Motley Fool

Summit Therapeutics: A Risky Bet in the Biotech Arena? ↗

October 24, 2025

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the odds, or is this stock a risky bet?

Via The Motley Fool

What's Going On With Summit Therapeutics Stock On Monday? ↗

October 20, 2025

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

Via Benzinga

Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗

October 20, 2025

Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.

Via Benzinga

Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss ↗

October 20, 2025

Summit Therapeutics reported a wider-than-expected Q3 2025 loss but is advancing its lead drug, ivonescimab, toward a key FDA submission.

Via Chartmill

Earnings Scheduled For October 20, 2025 ↗

October 20, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 08, 2025

Via Benzinga

1 Monster Stock in the Making to Buy and Hold ↗

October 05, 2025

This biotech company was relatively unknown a few years ago.

Via The Motley Fool

Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence ↗

October 01, 2025

Via Benzinga

Intel, Marvell, Electronic Arts Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 22 - Sep. 26): Are The Others In Your Portfolio? ↗

September 28, 2025

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

Via Benzinga

Nvidia High-Fives Palantir, Rocket Lab — On This List Of '10-Bagger' Legends ↗

September 23, 2025

Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom, showcasing the power and volatility of high-growth companies in a rapidly...

Via Benzinga

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 17, 2025

Via Benzinga

Jim Cramer: Ring The Register On This Real Estate 'Meme' Stock ↗

September 15, 2025

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ditching Opendoor: "We don't want to be in a meme stock."

Via Benzinga

Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio? ↗

September 14, 2025

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.

Via Benzinga

Topics Earnings

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

Top 3 Health Care Stocks You'll Regret Missing In Q3 ↗

September 09, 2025

Via Benzinga

Is Summit Therapeutics a Buy, Sell, or Hold Now? ↗

September 09, 2025

Western results for ivonescimab aren't lining up with the huge survival benefit measured in China.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 08, 2025

Via Benzinga

Gold Moves Higher; Robinhood Shares Jump ↗

September 08, 2025

Via Benzinga

Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗

September 08, 2025

Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.

Via Investor's Business Daily

Top movers in Monday's pre-market session ↗

September 08, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences ↗

September 08, 2025

Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.